Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (November 2024)
18 slides from Mimedx's investor presentation, Nov 18, 2024
Slide 1: Investor Presentation November 2024
Investor Presentation November 2024 Exhibit 99.1
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are
Slide 4: A Pioneer and Leader in Healing Solutions for Wound & Surgical
A Pioneer and Leader in Healing Solutions for Wound & Surgical Helping Humans Heal Our Why Our Vision To be the leading global provider of healing solutions through relentless innovation to restore quality of life. The most studied portfolio of placental-based products with 50+ clinical & scientific
Slide 5: The Unmet Need for Wound Healing Solutions Is Large and Growing
The Unmet Need for Wound Healing Solutions Is Large and Growing Ineffective Wound Management Leads to Poor Outcomes Favorable Demographic Trends Advances Driving Improved Outcomes for Patients million people suffer from chronic, non-healing wounds in the U.S.1 >10 Aging population Smoking history Di
Slide 6: Increasing Awareness of Massive Potential for Placental Tissue
Increasing Awareness of Massive Potential for Placental Tissue “Research has found placenta-derived grafts can reduce pain and inflammation, heal burns, prevent the formation of scar tissue and adhesions around surgical sites and even restore vision. They’re also gaining popularity as a treatment fo
Slide 7: The Patient Journey in Wound Care
The Patient Journey in Wound Care MIMEDX products are available in all settings where patients receive care… Private Office Wound Care Clinic Hospital Outpatient Assisted Living Facility …and other care settings Nursing Facility Mobile Health Home Health Hospital Inpatient …and are used on a range o
Slide 8: Building Library of Evidence for Surgical Applications
Building Library of Evidence for Surgical Applications Neuro Orthopedic Gastrointestinal Mohs Plastic OB/GYN Foot & Ankle Vascular Transplant Recent Publications Showcase Breadth of Potential Use Cases for MIMEDX Products in Surgery Cranioplasty Procedures with AMNIOFIX® EPIFIX® in Mohs Procedures C
Slide 9: Additional Surgical Studies in Process Focused on Significant Clinical Opportunities
Additional Surgical Studies in Process Focused on Significant Clinical Opportunities EPIFIX Mohs HECON AMNIOFIX in GI Anastomosis AMNIOFIX in Liver Transplant AMNIOFIX in Breast Reduction EPIFIX used in Mohs procedures associated with avoidance of postoperative complications and ancillary procedures
Slide 10: Our Strategic Priorities
Our Strategic Priorities helping humans heal. Develop & Deploy Programs to Expand Footprint in Surgical Enhance Customer Intimacy Continue momentum with new organic products in Wound & Surgical Consider additional inorganic additions to our product offering Drive further uptake of EPIFIX® in Japan I
Slide 11: Expanding Breadth of Skin Substitutes
Expanding Breadth of Skin Substitutes Leading Human-Derived Portfolio Emerging Xenograft Platform Innovative Offering for Surgical Market Best-in-Class Wound Product Portfolio Recently announced exclusive manufacturing and supply agreement with Regenity Biosciences. HELIOGEN builds on our goal to au
Slide 12: Worsening Medicare Spending Crisis Underscores Need for Overhaul
Worsening Medicare Spending Crisis Underscores Need for Overhaul 1) The Moran Company. (2024). Volume and Total Payment by Skin Substitute Product, CY 2019-2023. 2) ASP List refers to the Medicare Part B ASP Drug Pricing Files and CMS refers to the Centers for Medicare and Medicaid Services, Data So
Slide 13: LCDs Represent Critical First Step for Medicare Payment Overhaul
LCDs Represent Critical First Step for Medicare Payment Overhaul Additional reform still needed from CMS through modifications to the physician fee schedule Recently Updated LCDs Require Robust Clinical Data for Medicare Coverage 4 8 Feb. 12, 2025 Key Revisions from Proposed LCD Include: Application
Slide 14: Diversified Business by Product & Across Multiple Sites of Service
Diversified Business by Product & Across Multiple Sites of Service Site of Service Segment Commentary Hospital Setting (Inpatient & Outpatient) & Wound Care Clinics Stable reimbursement settings and growing with expanded use of products in surgical applications Private Office Medicare reimbursement
Slide 15: Commercial Organization with Scale, Leverage & Extensive Reach
Commercial Organization with Scale, Leverage & Extensive Reach Over 75 agencies with 200+ agents nationwide Extensive corporate support network Growing presence in Japan Over 200 direct sales professionals nationwide Over 300 million payer lives covered Experience selling more than 3 million allogra
Slide 16: Q3:24 Highlights
Q3:24 Highlights Gross Margin 82% Net Sales $84MM +3% year-over-year Adjusted EBITDA1 $18MM 22% of net sales 1) EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non-GAAP financial measures. See our Earnings Release for the quarter ended September 30, 2024 for a reconciliation to the n
Slide 17: Management Team with Track Record of Success in MedTech
Management Team with Track Record of Success in MedTech Joe Capper Chief Executive Officer Ricci Whitlow Chief Operating Officer Matt Notarianni Head of IR Kate Surdez Chief Human Resource Officer Butch Hulse Chief Administrative Officer & General Counsel John Harper, Ph.D. Chief Scientific Officer
Slide 18: Conclusion
Conclusion helping humans heal.